Mankind Pharma Ltd Share Price (MANKIND)
Check the latest share price of Mankind Pharma Ltd, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Mankind Pharma Ltd Stock Performance
Get live Mankind Pharma Ltd share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹2,344.1Day's Price Range₹2,386.752 Week's Low
52 Week's High
₹1,901.0552-Week Price Range₹3,054.8
| Returns % | |
| 1 Month Return | -6.78 % |
| 3 Month Return | + 9.69 % |
| 1 Year Return | + 6.28 % |
| 3 Year Return | + 67.43 % |
| 5 Year Return | + 67.43 % |
| Market Stats | |
| Previous Close | ₹2,390.00 |
| Open | ₹2,360.10 |
| Volume | 1.92L |
| Upper Circuit | ₹2,629.00 |
| Lower Circuit | ₹2,151.00 |
Mankind Pharma Ltd Fundamentals & Key Indicators
Check Mankind Pharma Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹1,21,573.55 Cr
Return on Equity (ROE)
15.5
PE Ratio (TTM)
23.05
Return on capital employed (ROCE)
20.1
Industry PE ratio
57.39
Beta (LTM)
0.71
P/B Ratio
4.31
Dividend Yield
0.87
PEG Ratio
1.62
Quarterly Earnings Growth YOY
-10.9
EPS (TTM)
51.47
Sector
Pharmaceuticals
Book Value
233.73
Technical Analysis
Bearish
View Technical Analysis
How to invest in Mankind Pharma Ltd?
Investing in Mankind Pharma Ltd is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Mankind Pharma Ltd or MANKIND on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Mankind Pharma Ltd or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Mankind Pharma Ltd with just a few clicks!
Mankind Pharma Ltd Stock's Interest Amongst Investors
Mankind Pharma Ltd Valuation
Track how Mankind Pharma Ltd P/E has moved over time to understand its valuation trends.
Mankind Pharma Ltd in the last 5 years
Lowest (40.63x)
August 5, 2024
Today (48.25x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (57.69x)
January 3, 2025
Today’s Price to Earnings Ratio: 48.25x
Mankind Pharma Ltd Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Mankind Pharma Ltd.
based on 17 analysts
76.47%
Buy
11.76%
Hold
11.76%
Sell
76.47% of analysts recommend a 'BUY' rating for Mankind Pharma Ltd. Average target price of ₹2712.47
Source: S&P Global Market Intelligence
Mankind Pharma Ltd Share Price Target
Get share price movements and forecasts by analysts on Mankind Pharma Ltd.
Mankind Pharma Ltd price forecast by 17 analysts
Upside of13.91%
High
₹3300
Target
₹2712.47
Low
₹2150
Mankind Pharma Ltd target price ₹2712.47, a slight upside of 13.91% compared to current price of ₹2381.3. According to 17 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Mankind Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2027:61.29%
Forecast
Actual
Including amortisation and stock based compensations
Mankind Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2027:38.87%
Forecast
Actual
Source: S&P Global Market Intelligence
Mankind Pharma Ltd Financial Results
Get the annual and quarterly financial summary of Mankind Pharma Ltd, including revenue, profit, loss and more.
Indices Featuring Mankind Pharma Ltd Stock
Check stock indices that include Mankind Pharma Ltd.
Mankind Pharma Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Mankind Pharma Ltd.
Mankind Pharma Ltd Earnings Results
Mankind Pharma Ltd’s net profit fell -10.71% since last year same period to ₹420.77Cr in the Q4 2024-2025. On a quarterly growth basis, Mankind Pharma Ltd has generated 10.66% jump in its net profits since last 3-months.
Read More about Earnings Results
Mankind Pharma Ltd Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Mankind Pharma Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 72.7% | 0.00 | |
| Foreign Institutions | 12.92% | 0.00 | |
| Mutual Funds | 7.67% | 0.00 | |
| Retail Investors | 2.9% | 0.00 | |
| Others | 3.81% | 0.00 |
Mankind Pharma Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Mankind Pharma Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 1,21,573.55 | 26.77% | 0.50 | 4,155 | 25,774 | |
| BUY | 1,10,074.44 | 32.82% | 0.67 | 1,656 | 10,727 | |
| HOLD | 1,76,987.90 | 37.1% | 0.50 | 1,600 | 7,845 | |
| BUY | 4,04,959.76 | 49.49% | 0.68 | 9,648 | 48,496 | |
| HOLD | 98,102.78 | 32.58% | 0.64 | 3,854 | 19,547 |
Mankind Pharma Ltd News & Key Events
Latest news and events in one place to help you make informed investing decisions in Mankind Pharma Ltd.
Mankind Pharma Launches Father's Day Campaign - 13 Jun, 2025
Mankind Pharma has launched a Father's Day campaign for HealthOK multivitamin tablets, celebrating fathers as HealthOK Heroes. The initiative emphasizes the importance of fathers' well-being and its connection to their children's health, supported by marketing across digital and traditional platforms.Mankind Pharma Allocates Shares Under ESOP - 10 Jun, 2025
Mankind Pharma has allotted 57,709 equity shares under its ESOP Plan, increasing its paid-up share capital. This move reflects the company's commitment to employee incentives.Mankind Pharma Shares Rise Amid Strong Financials - 30 May, 2025
Mankind Pharma shares rose by 2% to Rs 2511.10, reflecting positive market sentiment. The company has shown consistent revenue and net profit growth, with a projected increase in EPS by 2025. Despite a bearish market sentiment noted on May 23, 2025, the stock's recent performance indicates resilience.Mankind Pharma Expands Focus on Chronic Segments - 27 May, 2025
Mankind Pharma aims to grow in gastrointestinal and dermatology segments, developing a novel anti-obesity drug, and enhancing its women's health portfolio post-BSV acquisition. The company targets 18-20% growth from BSV products and plans to strengthen its brand presence.Mankind Pharma Aims for 26% Growth in FY26 - 23 May, 2025
Mankind Pharma is optimistic about achieving 26% growth in FY26, driven by chronic therapies and OTC products. Despite recent profit declines, the company remains focused on expanding its market presence and reducing debt. Leadership changes and portfolio realignment are underway to enhance growth potential.Mankind Pharma Q4 Results: Profit Declines, Revenue Rises - 21 May, 2025
Mankind Pharma's Q4 FY25 results show a 10.7% drop in net profit to ₹420.8 crore, despite a 27.1% revenue increase to ₹3,079.4 crore, driven by chronic therapies and consumer healthcare growth.Mankind Pharma Prepares for Q4 Results Amid Concerns - 20 May, 2025
Mankind Pharma is set to announce its Q4 results, with expectations of revenue growth but concerns over tariff-related risks and potential margin pressure affecting performance.Mankind Pharma Appoints Amitabh Bachchan as Brand Ambassador - 16 May, 2025
Mankind Pharma has appointed Amitabh Bachchan as its brand ambassador to promote good health and affordable treatment. The CEO expressed confidence that this partnership will enhance the brand's image among consumers.
Insights on Mankind Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 380.23 Cr → 420.77 Cr (in ₹), with an average increase of 9.6% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 5 quarters, 2.51K Cr → 3.33K Cr (in ₹), with an average increase of 6.6% per quarter
NO EFFECTRetail Holding Unchanged
Retail Investor holdings remained unchanged at 2.90% of holdings in Mar 2025 quarter
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 72.71% to 72.70% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, MANKIND stock has moved down by -6.8%
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 7.83% to 7.67% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 13.34% to 12.92% in Mar 2025 quarter
About Mankind Pharma Ltd
Revenue: ₹3,079.37Cr as on March 2025 (Q4 FY25)
Net Profit: ₹424.65Cr as on March 2025 (Q4 FY25)
Listing date: 09 May, 2023
Chairperson Name: RAMESH CHAND JUNEJA
| Organisation | Mankind Pharma Ltd |
| Headquarters | New Delhi |
| Industry | Pharmaceuticals |
| CEO | RAMESH CHAND JUNEJA |
| E-voting on shares | Click here to vote |
Mutual Funds that own Mankind Pharma Ltd
Check out the Mutual Funds with significant holdings in Mankind Pharma Ltd.
FAQs
What is Mankind Pharma Ltd share price today?
Mankind Pharma Ltd share price today stands at ₹2381.3, Open: ₹2360.1, Previous Close: ₹2390, High: ₹2386.7, Low: ₹2344.1, 52 Week High: ₹3054.8, 52 Week Low: ₹1901.05.
What is today's traded volume of Mankind Pharma Ltd?
Today's traded volume of Mankind Pharma Ltd is 1.92L. Which means that 1.92L shares of Mankind Pharma Ltd were bought and sold on the stock market during today's trading session.
What is Mankind Pharma Ltd's market cap today?
Today's market capitalisation of Mankind Pharma Ltd is ₹98,269.35 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Mankind Pharma Ltd?
Mankind Pharma Ltd’s 52 week high is ₹3054.8 and 52 week low is ₹1901.05. The current share price of Mankind Pharma Ltd is ₹2381.3, which is -22.05% down from its 52 week high and 25.26% up from its 52 week low.